NKGen Biotech, Inc. (NKGN)
OTCMKTS · Delayed Price · Currency is USD
0.0021
0.00 (0.00%)
Aug 31, 2026, 9:52 AM EST
NKGen Biotech Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
26
Market Cap
274.27K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 77.00K | -349.00K | -81.92% |
| Dec 31, 2021 | 426.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
NKGen Biotech News
- 2 months ago - NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel's Potential in Alzheimer's Disease and Other Neurodegenerative Conditions - GlobeNewsWire
- 3 months ago - NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment - GlobeNewsWire
- 5 months ago - NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit - GlobeNewsWire
- 5 months ago - NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™ - GlobeNewsWire
- 6 months ago - NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026 - GlobeNewsWire
- 7 months ago - NKGen Biotech appoints Bruce Miller to Scientific Advisory Board - TheFly
- 7 months ago - NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. - GlobeNewsWire
- 9 months ago - NKGen Biotech issues statement on NKGen Korea board appointments - TheFly